- receiving Lunsumio

  Show this card to any doctor involved in your care.
- Please carry this card with you at all times while you are

## Important Safety Information for Patients receiving LUNSUMIO (Mosunetuzumab) Patient Card



## Information for the Patient

Contact your Doctor or get emergency help **right away** if you have **any** of these. Cytokine Release Syndrome (CRS) symptoms to monitor for:

- Fever (100.4°F/38°C or higher)
- · Fast or irregular heartbeat
- · Chills or shaking chills
- Confusion
- Severe fatigue or weakness
- Dizziness or light-headedness
- Fainting
- Blurred vision
- · Cold or pale clammy skin
- Headache

Immune effector cell-associated neurotoxicity syndrome (ICANS) symptoms to monitor for:

- Confusion or disorientation
- Hallucinations (seeing, hearing or feeling things that are not there)
- Problems with language (difficulty with speech or change in speech)
- Seizures
- Problems with judgement (difficulty in problem-solving and making decisions)
- · Problems with memory
- Not being able to concentrate (difficulty staying awake)

 is a group of symptoms caused by small proteins called cytokines, released in your body during inflammation.
 may be caused by receiving Lunsumio.

Cytokine Release Syndrome



evaluation by a doctor.

Experiencing any of these symptoms could be due to Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS), which requires immediate

## Information for the Treating Doctor

This patient has received *Lunsumio* - which may cause Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS).

- 1 Evaluate the patient immediately and treat symptoms.
- If CRS or ICANS is suspected, please refer to section 2.2, Table 3 and Table 4 of the Singapore Package Insert for Lunsumio for comprehensive instructions on CRS and ICANS management.
- Contact the prescribing doctor when possible- they may need to modify the next infusion of *Lunsumio*

•							
Conta	ct	m	0	rm	atı	10	n

Prescribing doctor's phone number:		
Patient's name:		
Prescribing doctor's name:		
Date of Lunsumio initiation:		

For more information about *Lunsumio* please refer to the Singapore Package Insert

www.roche.com.sg/pharma/lunsumio



Company contact point: singapore.drugsafety@roche.com